CytoMed Therapeutics vs Scienture
GDTC and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GDTC and SCNX compare
CytoMed Therapeutics scores higher on the StockData Score (4 against 3 for Scienture), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GDTC | SCNX |
|---|---|---|
| Size and price | ||
| Market cap | – | $113M |
| Share price | $0.783 | $2.76 |
| Change, 1 year | −60.1% | −82.8% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | −0.42 | 1.19 |
| Employees | 5 | 8 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.8× |
| Growth | ||
| Revenue growth (TTM) | 367% | – |
| Revenue growth, 5Y average | – | −52.1% |
| Profitability | ||
| Net margin | −1227% | – |
| FCF margin | −1336% | – |
| Return on equity | −51.3% (better) | −53.5% |
| Return on invested capital | – | −47.3% |
| Financial health | ||
| Debt / equity | 0.06 | – |
| Interest coverage | – | −13.1× |
| Current ratio | 5.17 (better) | 3.04 |
| Altman Z-score | – | 0.07 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.10% | – |
| Held by insiders | 25.9% | 16.6% |
| Insider net buying, 12 months | $729K | – |
| Short interest, % of float | – | 0.34% |
Go deeper
- GDTC stock overview
- GDTC income statement
- GDTC valuation and score
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.